Source: Eur Respir J, 50 (1) 1700158; 10.1183/13993003.00158-2017
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Klaus F. Rabe, Peter M.A. Calverley, Fernando J. Martinez, Leonardo M. Fabbri. Effect of roflumilast in patients with severe COPD and a history of hospitalisation. Eur Respir J, 50 (1) 1700158; 10.1183/13993003.00158-2017

Member's Comments

No comment yet.

Related content which might interest you: Effect of roflumilast on exacerbations in patients with severe COPD and a prior history of hospitalization taking combination therapy Source: International Congress 2015 – Advances in the future treatment of COPD Year: 2015 Effect of roflumilast on hospitalizations in COPD patients Source: Annual Congress 2012 - COPD treatments: efficacy and safety Year: 2012 Long-term effect of roflumilast on exacerbations in patients with severe to very severe COPD Source: Eur Respir J 2006; 28: Suppl. 50, 526s Year: 2006 The effect of tiotropium/olodaterol versus tiotropium on COPD exacerbation rates in patients with/without frequent exacerbation history Source: International Congress 2019 – Exacerbations and clinical impact of airway diseases Year: 2019 Effect of exacerbation history and ICS use on outcomes in COPD patients from the TIOSPIR™ trial Source: International Congress 2015 – New data on established treatments for COPD Year: 2015 Effects of roflumilast in highly symptomatic COPD patients Source: Annual Congress 2012 - Effectiveness of therapeutic interventions in primary care Year: 2012 The 1-year cost-effectiveness of roflumilast for the treatment of severe to very severe COPD patients Source: Eur Respir J 2007; 30: Suppl. 51, 194s Year: 2007 Efficacy of roflumilast with concomitant cardiovascular medication in patients with COPD Source: Annual Congress 2013 –Novel mechanisms for established drugs for asthma and COPD management Year: 2013 β-blockers and risk of COPD exacerbation requiring hospitalisation in patients with COPD Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD Year: 2011 Effect of dupilumab on severe exacerbations in asthma patients with and without lung function improvements Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma Year: 2020 Impact of moderate and severe exacerbations in severe COPD patients Source: International Congress 2018 – How far are we in terms of predicting mortality and exacerbations in COPD? Year: 2018 Extrafine triple therapy in patients with symptomatic COPD and history of one moderate exacerbation Source: Eur Respir J, 53 (5) 1900235; 10.1183/13993003.00235-2019 Year: 2019 Influence of statin therapy on exacerbation frequency in patients with COPD Source: Annual Congress 2009 - Drug effects in COPD Year: 2009 Influence of bronchiectasis in patients hospitalized due to acute exacerbation of COPD. Source: International Congress 2017 – Towards personalised medicine in COPD: biological and clinical phenotypes Year: 2017 Severe outcomes of COVID-19 among patients with COPD and asthma Source: ERJ Open Res, 7 (1) 00594-2020; 10.1183/23120541.00594-2020 Year: 2021 Triple therapy for all patients with severe symptomatic COPD at risk of exacerbations Source: Eur Respir J, 53 (4) 1900147; 10.1183/13993003.00147-2019 Year: 2019 Physiological impairments and exacerbation risk in COPD patients with less symptom and no frequent exacerbation history. Source: Virtual Congress 2021 – Prediction of exacerbations in patients with COPD Year: 2021 Markers of T2-inflammation in patients with severe asthma and concomitant COPD Source: Virtual Congress 2020 – News on clinical evaluation of bronchiectasis, cough and inflammatory disease Year: 2020 Predictors of severe exacerbations in patients with moderate and severe asthma Source: International Congress 2018 – Determinants and monitoring of asthma control Year: 2018 Characterization of readmissions in patients hospitalized with COPD exacerbation Source: International Congress 2016 – Novel avenues in the treatment of COPD II Year: 2016